Backed Research
Investment Thesis
Backed is a London-based European seed fund founded in 2016 by Andre de Haes and Alex Brunicki. The through-line is consistent: invest in Europe's generational founders building frontier technology companies that combine a real technical or conceptual breakthrough with global ambition. The firm explicitly frames itself as a community-oriented investor and platform, not just a source of capital. It sits at the intersection of venture and events, hosts about 40 events a year, and says its support extends from seed to Series A and beyond. Recent writing expands that thesis into three core themes: the future of healthcare, the future of finance, and the future of manufacturing. That lines up with the current portfolio and with Fund 3, which is pointed at AI-native therapeutics, blockchain and banking infrastructure, and manufacturing automation.
Stage Focus
Backed is an early-stage investor. The public ethos page says 80% of investments have been at the pivotal early stage, and the fund describes itself as leading seed rounds while occasionally backing pre-seed companies and re-backing its strongest founders. The public material also points to a strong lead or co-lead tendency: the firm says it leads or co-leads most Fund 3 deals, and the latest fund announcement says Backed 3 is already re-investing in six prior founders. For a firm like this, the practical read is: pre-seed and seed are the sweet spot, with selective support as companies move toward Series A and later financings.
Check Size
Backed publicly states seed tickets from $500K to $5M, and the Fund 3 launch repeats that range. That is a fairly wide check size for early stage, which fits a lead or co-lead posture and makes sense for companies that need enough capital to accelerate from technical insight to real product traction. I’d treat $500K as the conservative lower bound and $5M as the upper bound for the firm’s core seed behavior.
Lead Tendency
Backed is best described as a lead-oriented seed investor. The firm says it led or co-led 92% of Backed 3 deals on the ethos page, and the Fund 3 announcement goes further, describing Backed as leading or co-leading 100% of Backed 3 deals. The broader pattern is consistent even where the round is not led outright: Backed wants a high-conviction seat, early access, and meaningful support around the company. The public material and founder testimonials emphasize trust, long-term support, and a willingness to be the first institutional believer.
Recent Activity
The clearest recent anchor is the 13 November 2025 announcement that Backed closed Backed 3 at the $100M cap and marked its 100th investment. The same announcement says the fund focuses on AI-native therapeutics, blockchain and banking infrastructure, and manufacturing automation. On 27 May 2025, Backed announced its investment in Infinity Constellation, an AI incubator and holding company that stepped out of stealth after a $12M round and reached $17M total funding. A separate 2025 insight on the foundation-labs theme shows the firm continuing to think deeply about AI x biology, and the LONDON BIO anniversary post shows the firm still building community around the same healthcare thesis. The public portfolio page also shows active seed-stage additions like GingerControl and Aerska.
Portfolio Highlights
The portfolio demonstrates breadth but not randomness. It includes frontier-tech names across fintech, healthcare, manufacturing, and gaming. Notable examples from the public portfolio and articles include Banked, CloudNC, CoMind, Aerska, GingerControl, General Intuition, Ochre-Bio, LabGenius, Immutable, Medal, Hutch, and Cala. The presence of both acquisitions and unicorns suggests a long-running platform with several realized outcomes, not a short-lived thematic fund. The public site also references six unicorns and multiple companies above €25M ARR and $100M+ enterprise value.
Team
Backed’s founders are Andre de Haes and Alex Brunicki, both co-founders and general partners. The team page also shows Alexey Morgunov as a Venture Partner focused on AI x Bio, which reinforces the healthcare and biology theme. The broader team includes operators and specialists in brand, finance, portfolio support, and investing, which matches the firm’s community-first positioning. The public founder testimonials repeatedly stress that the team is hands-on, trusted, and unusually effective at supporting founders beyond the initial check.
Decision Process
The public material points to a partnership-driven process rather than a solo-GP or loose committee model. Backed repeatedly emphasizes conviction, founder trust, and deep relationships, and the events platform is clearly part of how the firm sources and builds conviction. I would expect a fairly fast early-stage process, but I did not find a hard public timeline, so I’m leaving that unpinned rather than guessing.
Founder Preferences
Backed favors brave founders building globally relevant companies, usually from Europe but not limited to Europe if the company is stronger elsewhere. The firm looks for technical or scientific edge, first-principles thinking, and a willingness to tackle hard, underexplored problems. It also appears to value founders who can participate in the community the firm is building; the public writing repeatedly frames founders as long-term partners and future LPs, not just deal recipients. A human-centric culture is part of the pitch: be an awesome human above all else.
Geographic Focus
Backed is rooted in Europe, and London is the clearest headquarters signal in the public material. But Fund 3 explicitly says the firm is increasing its presence in the US, and several portfolio companies are already building in the US when that is the best place to do so. The practical geographic read is Europe-first with a transatlantic posture for the right technical company.